Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Autolus Therapeutics plc ADR (NASDAQ: AUTL) closed at $4.56 in the last session, up 0.88% from day before closing price of $4.52. In other words, the price has increased by $0.88 from its previous closing price. On the day, 1.15 million shares were traded. AUTL stock price reached its highest trading level at $4.6495 during the session, while it also had its lowest trading level at $4.475.
Ratios:
We take a closer look at AUTL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.11 and its Current Ratio is at 6.11. In the meantime, Its Debt-to-Equity ratio is 2.01 whereas as Long-Term Debt/Eq ratio is at 1.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on November 09, 2023, initiated with a Buy rating and assigned the stock a target price of $10.
On March 17, 2023, Bryan Garnier started tracking the stock assigning a Buy rating and target price of $5.Bryan Garnier initiated its Buy rating on March 17, 2023, with a $5 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUTL now has a Market Capitalization of 1212622592 and an Enterprise Value of 1196923904. For the stock, the TTM Price-to-Sale (P/S) ratio is 467.00 while its Price-to-Book (P/B) ratio in mrq is 7.12. Its current Enterprise Value per Revenue stands at 704.902 whereas that against EBITDA is -7.084.
Stock Price History:
The Beta on a monthly basis for AUTL is 1.99, which has changed by 1.635838 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, AUTL has reached a high of $7.45, while it has fallen to a 52-week low of $1.61. The 50-Day Moving Average of the stock is -22.40%, while the 200-Day Moving Average is calculated to be 4.44%.
Shares Statistics:
According to the various share statistics, AUTL traded on average about 1.54M shares per day over the past 3-months and 964970 shares per day over the past 10 days. A total of 174.10M shares are outstanding, with a floating share count of 157.78M. Insiders hold about 9.38% of the company’s shares, while institutions hold 61.01% stake in the company. Shares short for AUTL as of 1711584000 were 4168216 with a Short Ratio of 2.70, compared to 1709164800 on 2769469. Therefore, it implies a Short% of Shares Outstanding of 4168216 and a Short% of Float of 2.12.
Earnings Estimates
The market rating for Autolus Therapeutics plc ADR (AUTL) is a result of the insights provided by 4 analysts actively involved in the assessment.On average, analysts expect EPS of $-0.05 for the current quarter, with a high estimate of $0.42 and a low estimate of $-0.28, while EPS last year was $-0.23. The consensus estimate for the next quarter is $-0.2, with high estimates of $-0.15 and low estimates of $-0.3.
Analysts are recommending an EPS of between $-0.46 and $-1.23 for the fiscal current year, implying an average EPS of $-0.71. EPS for the following year is $-0.59, with 8 analysts recommending between $-0.37 and $-0.95.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for AUTL’s current fiscal year. The highest revenue estimate was $57M, while the lowest revenue estimate was $2.59M, resulting in an average revenue estimate of $36.88M. In the same quarter a year ago, actual revenue was $1.7M, up 2,072.00% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $102.1M in the next fiscal year. The high estimate is $283.1M and the low estimate is $39.23M. The average revenue growth estimate for next year is up 176.80% from the average revenue estimate for this year.
